Loading
Amedisys Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Dec 2021.
Amedisys Inc: what insiders have been doing
This page follows insider dealings at Amedisys Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in United States. The group dates from 1982. No insider at Amedisys Inc has published a filing in the past twelve months. The most recent one dates from 14 August 2025.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
144
Thresholds
n/a
Buy Volume
€125,073
1 ops. · all time
Sell Volume
€1M
23 ops. · all time
Who traded when
BuySaleAllyson Guidroz2 sales
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$2B
Net incomeUS$37.2M1.8% margin
Last declaration on 14 August 2025
Declarations144 total
9,818 sharesCommon StockSEC:0000896262-25-000082:0
23,992 sharesCommon StockSEC:0000896262-25-000075:0
8,818 sharesCommon StockSEC:0000896262-25-000088:0
16,031 sharesCommon StockSEC:0000896262-25-000087:0
439,124 sharesCommon StockSEC:0000896262-25-000086:0
9,335 sharesCommon StockSEC:0000896262-25-000085:0
3,067 sharesCommon StockSEC:0000896262-25-000084:0
9,818 sharesCommon StockSEC:0000896262-25-000083:0
10,700 sharesCommon StockSEC:0000896262-25-000081:0
31,211 sharesCommon StockSEC:0000896262-25-000080:0
9,283 sharesCommon StockSEC:0000896262-25-000079:0
898 sharesCommon StockSEC:0000896262-25-000078:0
45,870 sharesCommon StockSEC:0000896262-25-000077:0
7,600 sharesCommon StockSEC:0000896262-25-000076:0
2,015 shares0Common StockSEC:0000896262-25-000067:0
31 shares@ US$97.941.7% of flowCommon StockSEC:0000896262-25-000057:0
25 shares@ US$97.940.7% of flowCommon StockSEC:0000896262-25-000059:0
105 shares0Common StockSEC:0000896262-25-000054:0
461 shares@ US$96.3811.2% of flowCommon StockSEC:0000896262-25-000051:0
2,327 shares@ US$98.0321.1% of flowCommon StockSEC:0000896262-25-000050:0
171 shares@ US$94.074.7% of flowCommon StockSEC:0000896262-25-000049:0
374 shares@ US$96.0010.7% of flowCommon StockSEC:0000896262-25-000047:0
273 shares@ US$96.007.8% of flowCommon StockSEC:0000896262-25-000046:0
1,690 shares0Common StockSEC:0000896262-25-000042:0
1,690 shares0Common StockSEC:0000896262-25-000040:0
25 of 144 declarations
About Amedisys Inc
Amedisys Inc. (ticker: AMED) is a United States-based home-based healthcare company focused on home health, hospice, and higher-acuity care delivered in the patient’s home. The company is listed in the U.S. market on NYSE/NASDAQ and is headquartered in Baton Rouge, Louisiana, with an executive office in Nashville, Tennessee. Amedisys was founded in 1982 and has built its business around the structural shift toward lower-cost, more patient-friendly care settings outside the acute hospital environment.
The company’s core operating model is centered on Medicare-certified care centers and a clinically integrated service portfolio. Its home health business provides skilled nursing, therapy, and related services for patients recovering from illness, injury, or surgery, or managing chronic conditions. Its hospice platform offers end-of-life care with medical, emotional, and spiritual support for patients and families. Amedisys also offers palliative care and hospital-level or skilled-nursing-type care at home through Contessa, an Amedisys company. This broader care continuum allows the group to address multiple stages of the patient journey and deepen relationships with physicians, hospitals, and payors.
Read moreShow less
From a competitive standpoint, Amedisys has long been regarded as one of the established players in the U.S. home health and hospice market. The segment remains highly regulated and operationally demanding, with reimbursement dynamics—especially Medicare—playing a central role in profitability and growth. Amedisys has disclosed that a large majority of its consolidated net service revenue historically comes from Medicare, underscoring both the defensiveness of the model and its exposure to reimbursement and compliance changes. As of December 31, 2024, the company operated 347 Medicare-certified home health care centers, 164 Medicare-certified hospice care centers, and 8 admitting high-acuity care joint ventures across 38 states and the District of Columbia.
Recent developments have been significant. Amedisys divested its personal care business in 2023, sharpening its strategic focus on core home health, hospice, and higher-acuity services. The most important corporate event has been its merger agreement with UnitedHealth Group, announced in June 2023 and completed in August 2025 according to SEC filings. That transaction effectively transformed Amedisys from an independent listed healthcare operator into part of a larger managed-care and healthcare-services platform. For investors, AMED is best viewed as a U.S. healthcare-at-home platform with a strong defensive profile, a Medicare-linked revenue base, and a strategic history shaped by consolidation in the home-based care industry.
